- Home
- NCPL vs ENSC Comparison
NCPL vs ENSC Comparison
Compare NCPL & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- ENSC
- Stock Information
- Founded
- NCPL 1984
- ENSC 2003
- Country
- NCPL United States
- ENSC United States
- Employees
- NCPL N/A
- ENSC N/A
- Industry
- NCPL Investment Managers
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- ENSC Health Care
- Exchange
- NCPL Nasdaq
- ENSC Nasdaq
- Market Cap
- NCPL 4.3M
- ENSC 4.9M
- IPO Year
- NCPL N/A
- ENSC N/A
- Fundamental
- Price
- NCPL $4.08
- ENSC $2.20
- Analyst Decision
- NCPL
- ENSC
- Analyst Count
- NCPL 0
- ENSC 0
- Target Price
- NCPL N/A
- ENSC N/A
- AVG Volume (30 Days)
- NCPL 568.1K
- ENSC 232.3K
- Earning Date
- NCPL 07-28-2025
- ENSC 08-13-2025
- Dividend Yield
- NCPL N/A
- ENSC N/A
- EPS Growth
- NCPL N/A
- ENSC N/A
- EPS
- NCPL N/A
- ENSC N/A
- Revenue
- NCPL $812,612.00
- ENSC $6,224,081.00
- Revenue This Year
- NCPL N/A
- ENSC N/A
- Revenue Next Year
- NCPL $101.16
- ENSC $1,381.48
- P/E Ratio
- NCPL N/A
- ENSC N/A
- Revenue Growth
- NCPL N/A
- ENSC 256.35
- 52 Week Low
- NCPL $1.41
- ENSC $1.62
- 52 Week High
- NCPL $11.90
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- NCPL 68.27
- ENSC 48.64
- Support Level
- NCPL $3.82
- ENSC $2.02
- Resistance Level
- NCPL $5.75
- ENSC $2.15
- Average True Range (ATR)
- NCPL 0.63
- ENSC 0.17
- MACD
- NCPL 0.15
- ENSC 0.01
- Stochastic Oscillator
- NCPL 53.87
- ENSC 36.21
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.